SCHEMBL2665231

SCHEMBL2665231

CC1CSC(Cc2ccccc2)=N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.38
NOS1 P29475 2/20 0.36
NOS2 P35228 2/20 0.36
ALDH1A1 P00352 3/20 0.34
GLA P06280 2/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 2/20 0.33
NPY1R P25929 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
HPGD P15428 2/20 0.33
ALOX15 P16050 1/20 0.33
ALPL P05186 1/20 0.33
CYP3A4 P08684 1/20 0.33
EPHX2 P34913 1/20 0.33
ADRA2A P08913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10078144 0.76 CYP1A2 (0.39) CALM1ALDH1A1L3MBTL1LMNACYP1A2
SCHEMBL1963688 0.64 TAAR1 (0.47) CALM1NOS1NOS2L3MBTL1LMNA
SCHEMBL28004642 0.64 TAAR1 (0.43) CALM1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL11138492 0.63 NOS1 (0.41) CALM1NOS1NOS2CYP1A2CYP2D6
SCHEMBL12432904 0.62 TAAR1 (0.41) NOS1NOS2ALDH1A1RAB9ASMN1; SMN2
SCHEMBL28298668 0.62 CALM1 (0.50) CALM1NOS1NOS2ALDH1A1GLA
SCHEMBL6972859 0.61 TAAR1 (0.40) NOS1NOS2ALDH1A1LMNACYP1A2
SCHEMBL6975809 0.61 ALPL (0.38) NOS1NOS2ALDH1A1LMNANPY1R
Diphenylmethane SCHEMBL27450549 0.61 CALM1 (0.86) CALM1ALDH1A1LMNACYP3A4TSHR
Diphenylmethane SCHEMBL1303 0.60 CALM1 (1.00) CALM1ALDH1A1LMNAHPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812048-B2 Glucokinase activators and methods of using same BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-12 US disclosed
US-20090030046-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030046-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, HK1 CALM1 2061/4885NOS1 1832/4885NOS2 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.